In severe ICI-myopathy-myocarditis refractory to first-line therapy, escalation with IL-6 receptor blockade was temporally associated with limb muscle strength improvement and favorable long-term functional outcomes among survivors.
Tocilizumab was used as second-line therapy in 8 of 11 patients with severe ICI-myopathy-myocarditis after failure of first-line immunosuppression.
Weakness improved in all patients who received tocilizumab, but only 4 of 8 survived hospitalization.
Among acute-phase survivors, long-term functional outcomes were favorable, with a final median CTCAE grade of 1.
Limb strength normalized before oculobulbar weakness resolved in survivors.
Most survivors demonstrated partial oncologic response to their underlying cancer treatment, followed by later disease progression at a median of 8 months.
The IL-6 pathway is implicated in ICI-myopathy, providing a mechanistic rationale for tocilizumab use as escalation therapy.
This research describes what happened to 11 patients who developed a serious side effect called immune checkpoint inhibitor (ICI) myopathy-myocarditis — a condition where cancer immunotherapy drugs accidentally cause the immune system to attack the heart and muscles. Despite being a recognized complication of modern cancer treatments, this condition carries very high mortality even when treated. The researchers tracked outcomes for patients admitted to a Canadian hospital, focusing especially on those who received a drug called tocilizumab (which blocks a specific immune signaling molecule called IL-6) when standard first-line treatments were not enough. This research suggests that tocilizumab was associated with muscle strength improvements in all patients who received it, but the overall outlook remained serious — only 4 of the 8 patients who received tocilizumab survived their hospitalization. Among those who did survive, longer-term outcomes were more encouraging: most showed significant functional recovery (with residual disability rated as only mild), and most also showed partial responses in their underlying cancers, though cancer progression tended to occur around 8 months later. Notably, limb strength tended to recover before eye and throat muscle weakness, suggesting different muscle groups recover at different rates. This study matters because ICI-myopathy-myocarditis is a dangerous and increasingly recognized complication as immunotherapy becomes more widely used in cancer treatment. The findings provide early evidence that tocilizumab might be a useful second-line treatment option for patients who do not respond to initial therapy, and they offer important information about what recovery can look like for survivors. The authors call for further, larger studies to more rigorously evaluate this treatment approach in this high-risk patient population.
Chaggar G, Mulvany-Robbins B, Anaka M, Putko B, Beecher G. (2026). Tocilizumab for severe immune checkpoint inhibitor myopathy-myocarditis: acute and long-term outcomes.. Journal of neurology. https://doi.org/10.1007/s00415-026-13923-w